About MDxHealth
MDxHealth SA ADR (EBR:MDXH), (NASDAQ:MDXH) specializes in providing actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company focuses on developing and marketing a range of novel genomic and epigenetic tests that assist physicians in the diagnosis and prognosis of cancer patients, as well as in predicting patients' response to certain treatments. Its flagship products are aimed at prostate, bladder, and kidney cancers, employing state-of-the-art genomics technologies to provide accurate and actionable insights. MDxHealth’s objective is to improve patient outcomes by leveraging molecular diagnostics that can lead to earlier detection and more personalized treatment approaches, ensuring better management of the disease. The company is dedicated to innovation in cancer care, continuously working on expanding its product portfolio and improving the precision of cancer diagnostics.
Snapshot
Operations
Products and/or services of MDxHealth
- ConfirmMDx, a prostate cancer test helping to reduce unnecessary biopsies by identifying patients at low risk.
- SelectMDx, a non-invasive urine test that assesses the risk of prostate cancer before biopsy.
- AssureMDx, a bladder cancer detection test designed for individuals with hematuria (blood in urine).
- MonitorMDx, a test for assessing prostate cancer recurrence risk post-treatment.
- InformMDx, a diagnostic tool aimed at identifying aggressive forms of prostate cancer.
- MatchMDx, a service designed to guide urologic oncology treatments by matching patients’ genetic profiles with suitable therapies.
MDxHealth executive team
- Mr. Michael K. McGarrityCEO & Executive Director
- Mr. Joseph Sollee J.D., LLMExecutive VP of Corporate Development & General Counsel
- Mr. John A. BellanoChief Commercial Officer
- Mr. Scott McMahanVice President of Finance and Accounting & Interim CFO
- Ms. Miriam ReyesExecutive Vice President of Operations
- Ms. Kim LerouxExecutive Vice President of Revenue Cycle Management